Skip to main content
. 2020 Jul 21;21(14):5164. doi: 10.3390/ijms21145164

Figure 4.

Figure 4

(A) Percentage distribution of small molecule inhibitors from various targets in NF-κB pathways reached in the clinic for different indications. (B) Similarly, the number of small molecule inhibitors from various targets in NF-κB pathways placed in phase 1(P1), phase 2(P2), phase 3(P3), and launched (L) in clinical trials.